Recent advances in Helicobacter pylori eradication

Th e most popular regimen for eradication of Helicobacter pylori (H. pylori) infection is triple therapy, composed of a potent proton pump inhibitor (PPI), amoxicillin (AMOX), and clarithromycin (CLA). Emerging resistance to CLA changed this strategy, and according to Maastricht IV recommendation, this regimen can be used only in countries with low (<20%) CLA resistance [1]. A regimen for the treatment of H. pylori is now acceptable if it is associated with at least 90 % success [2]. In addition to CLA resistance several other factors may infl uence the success or failure of H. pylori eradication: duration of therapy and dosage, PPI eff ect on gastric acid secretion, other drugs ’ resistance, and patients ’ compliance. Regardless of the antibiotic used, prolonging treatment duration from 7 to 14 days signifi cantly improved eradication rates [3]. PPI is an important part of the treatment protocol, since a gastri